2021-03-15T12:27:32Z
2021-03-15T12:27:32Z
2021-02-14
2021-03-11T11:16:01Z
This single-center, retrospective cohort study sought to estimate the cumulative incidence in HIV-1-infected patients of biopsy-proven high-grade anal intraepithelial neoplasia (HGAIN) recurrence after infrared coagulation (IRC) treatment. The study was based on data from a prospectively compiled database of 665 HIV-1-infected outpatients who attended a hospital Clinical Proctology/HIV Unit between January 2012 and December 2015. Patient records were checked to see which ones had received IRC treatment but later experienced a recurrence of HGAIN. Cytology samples were also checked for the presence of human papilloma virus (HPV). A total of 81 of the 665 patients (12%, 95%CI: 10-15%), of whom 65 were men and 16 women, were diagnosed with HGAIN and again treated with IRC. Of these 81, 20 (25%) experienced recurrent HGAIN, this incidence being true of both men (16/65, 95%CI: 19-57%) and women (4/16, 95%CI: 10-50%). The median time to recurrence was 6 (2-19) months overall, 6 (2-19) months in men, and 4 (2-6) months in women. HPV infection was detected in all patients except two, with HPV-16 being the most common genotype. This rate of incidence of recurrent HGAIN following IRC treatment is consistent with other reports and highlights the importance of continued post-treatment surveillance, particularly in the first year.
Article
English
Infeccions per VIH; Malalties de l'anus; HIV infections; Diseases of the anus
MDPI AG
Reproducció del document publicat a: https://doi.org/10.3390/pathogens10020208
Pathogens, 2021, vol. 10, num. 208
https://doi.org/10.3390/pathogens10020208
cc by (c) Corral, Javier et al., 2021
http://creativecommons.org/licenses/by/3.0/es/